EDIT Editas Medicine
- 5.060
- -0.430-7.83%
- 5.120
- +0.060+1.19%
Editas Medicine News
Editas Medicine Says Its Gene Editing Potential Treatment for Sickle-Cell Disease Found Well-Tolerated in Phase 1/2 Trial
Editas Medicine (EDIT) said Friday that new data in a phase 1/2 trial of its gene-editing cell therapy medicine renizgamglogene autogedtemcel showed its was "well-tolerated" and had a safety profile c
Editas Medicine Reveals Updated Safety And Efficacy Results From The RUBY Trial Of Reni-Cel In 18 Sickle Cell Patients At EHA
All patients treated in the RUBY trial are free of vaso-occlusive events post-renizgamglogene autogedtemcel (reni-cel) infusionPatients had early normalization of total hemoglobin with a mean within t
Express News | Editas Medicine Inc - All Patients Treated in Edithal Trial Maintained Hemoglobin Levels Above Transfusion Threshold and Are Transfusion-Free
Express News | Editas Medicine Announces New Safety and Efficacy Data From the Edithal Trial of Reni-Cel in 7 Patients With Transfusion-Dependent Beta Thalassemia, Presented at the European Hematology Association (Eha) Annual Congress
Form 144 | Editas Medicine(EDIT.US) Officer Proposes to Sell 127.68K in Common Stocks
SEC FILLINGS DISCLOSED/ May 31, $Editas Medicine(EDIT.US)$ Officer O'Neill Gilmore Neil intends to sell 24,000 shares of its common stock on Jun 3, with a total market value of approximately $127.68K.
The Analyst Verdict: Editas Medicine In The Eyes Of 4 Experts
Across the recent three months, 4 analysts have shared their insights on Editas Medicine (NASDAQ:EDIT), expressing a variety of opinions spanning from bullish to bearish.The table below offers a conde
Editas Medicine Is Maintained at In-Line by Evercore ISI Group
Editas Medicine Is Maintained at In-Line by Evercore ISI Group
Express News | Editas Medicine Inc : Evercore ISI Cuts Target Price to $7 From $15
Azzur Cleanrooms on Demand Grand Opening in Devens, MA Brings Together Local, State and Life Sciences Leaders
DEVENS, Mass., May 28, 2024 /PRNewswire/ -- Azzur Cleanrooms on Demand, a market-leading service provider for life sciences GxP manufacturing and testing capacity, recently hosted a Grand Opening and
EVP, Chief Financial Officer Erick Lucera Sells 22,337 Shares of Editas Medicine Inc (EDIT)
Form 144 | Editas Medicine(EDIT.US) Officer Proposes to Sell 256.95K in Common Stocks
SEC FILLINGS DISCLOSED/ May 17, $Editas Medicine(EDIT.US)$ Officer Lucera Erick intends to sell 45,000 shares of its common stock on May 17, with a total market value of approximately $256.95K. Sou
Director Jessica Hopfield Acquires 45,000 Shares of Editas Medicine Inc (EDIT)
On May 13, 2024, Jessica Hopfield, Director at Editas Medicine Inc (NASDAQ:EDIT), purchased 45,000 shares of the company, as reported in the SEC Filing.
Editas Medicine(EDIT.US) Director Buys US$253.87K in Common Stock
$Editas Medicine(EDIT.US)$ Director Hopfield Jessica purchased 45,000 shares of common stock on May 13, 2024 at an average price of $5.6415 for a total value of $253.87K.Source: Announcement What is s
Editas Medicine Insider Bought Shares Worth $253,868, According to a Recent SEC Filing
Jessica Hopfield, Director, on May 13, 2024, executed a purchase for 45,000 shares in Editas Medicine (EDIT) for $253,868.
Editas Medicine to Present Clinical Data From the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today announced that two abstracts, including one oral presentation and one poster
Editas Medicine, Inc. (NASDAQ:EDIT) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Editas Medicine, Inc. (NASDAQ:EDIT) missed earnings with its latest quarterly results, disappointing overly-optimistic forecasters. Statutory earnings fell substantially short of expectations, wi
Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Editas Medicine Preclinical Data Highlights Advancement of in Vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
Research includes the first-ever application of AsCas12a in vivo, optimized LNP delivery, and gene editing RNA guide modifications Data to support development of the Company's in vivo gene editing medicines pipeline
Buy Rating Affirmed for Editas Medicine Amid Promising CRISPR Pipeline and Growth Potential
Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call Transcript
Analysis
Price Target
No Data
